Regression of fibrosis in HCV with long-term interferon treatment

Regression of hepatic fibrosis in hepatitis C with long-term interferon treatment.
Dufour JF, DeLellis R, Kaplan MM
Department of Pathology, New England Medical Center, Tufts University Medical School, Boston, Massachusetts 02111, USA.

Cirrhosis occurs in 20-50% of patients with hepatitis C and is thought to be irreversible. We describe two patients with cirrhosis secondary to hepatitis C in whom the extensive fibrosis and cirrhosis appeared to regress in response to treatment with interferon-alpha (IFN-alpha). Both patients were in the early stages of cirrhosis, class A in the Child-Pugh classification, total score 5 for each patient. Both responded fully to IFN-alpha and had normalization of all liver function tests and disappearance of hepatitis C viral RNA. Liver biopsies, performed before and after treatment, were coded unpaired by patient, combined with 21 liver biopsies from eight other patients with chronic hepatitis, and read independently by two pathologists using the Knodell scoring system. Knodell scores decreased from 14 to 3.5 and from 13.5 to 4 in these two patients. Cirrhosis and extensive fibrosis, present at baseline, were not present on follow-up liver biopsies, which were of sufficient size to reduce the likelihood of sampling error. We conclude that hepatic fibrosis and clinically early cirrhosis may be reversible in some patients with hepatitis C who respond to treatment with IFN-alpha.

PMID: 9881484, UI: 99095811

Advertisement
Hepatitis C Primer Home

What is Hepatitis How is Hepatitis Transmitted

Long-term Prognosis

Complications of HCV Liver Biopsy Treatment Info (Interferon, Herbal, etc) Lab Tests (PCR, Genotype,etc.) Nutrition & Alternative Info

Patient Information (Support Groups, Doctor Listing, etc) Related Webpages Transplant Info Site Search HCV Webrings Guestbook FAQ & Disclaimers

Triple Therapy Reduces Hepatitis C Drug Resistance
A review in the February 2010 issue of Gastroenterology sites viral resistance against new medications as incentive for using triple therapy to treat Hepatitis C.

Three HCV Drug Candidates Proceed to Phase II
Hepatitis C drug candidates ABT-450, ABT-333 and ABT-072 move into Phase II testing.

Should Those with HCV Be Concerned About Bathing?
Find out how some with Hepatitis C unintentionally expose their skin to bath water contaminants that can place an additional burden on their liver.

More Hep C articles ...